17.06.2024 14:02:15 - dpa-AFX: *J&J :SUBCUTANEOUS AMIVANTAMAB BLA SUBMITTED TO FDA FOR PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
Johnson & Johnson 853260 NYSE 147,120 26.06.24 20:48:47 -0,070 -0,05% 147,110 147,120 146,200 147,190

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH